- $5.16m
- -$1.87m
- $0.43m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 0.84 | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.23 | ||
| Price to Tang. Book | 0.23 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -43.07% | ||
| Return on Equity | 0.08% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 0.54 | 0.91 | 1.54 | 1.3 | 0.43 | 31.2 | 65.7 | 2.38% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Aptorum Group Limited is a United Kingdom-based clinical stage biopharmaceutical company dedicated to the discovery, development and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. Its lead projects are ALS-4, SACT-1 and PathsDx Test. ALS-4 is a small drug molecule which appears to target the products produced by bacterial genes that facilitate the successful colonization and survival of the bacterium in the body or that cause damage to the body's systems. SACT-1 is the first repurposed drug candidate to be developed under the Smart-ACT drug discovery platform. The Company's pipeline is also enriched through the co-development of PathsDx Test, a novel molecular-based rapid pathogen identification and detection diagnostics technology, with Accelerate Technologies Pte Ltd, commercialization arm of the Singapore's Agency for Science, Technology and Research.
Directors
- Darren Lui PRE (40)
- Ian Huen CEO (41)
- Sabrina Khan CFO (39)
- Angel Ng COO (40)
- Clark Cheng EDR (41)
- Thomas Lee OTH (48)
- Douglas Arner NID (51)
- Charles Bathurst NID (65)
- Mirko Scherer NID (52)
- Justin Wu NID (51)
- Last Annual
- December 31st, 2023
- Last Interim
- June 30th, 2024
- Incorporated
- September 13th, 2010
- Public Since
- December 18th, 2018
- No. of Shareholders
- 27
- No. of Employees
- 3
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
NASDAQ Capital Market- Shares in Issue
- 5,608,757
- Address
- 17 Hanover Square, LONDON, W1S 1BN
- Web
- https://www.aptorumgroup.com/
- Phone
- +44 2080929299
- Auditors
- Marcum Bernstein & Pinchuk LLP
Upcoming Events for APM
Similar to APM
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
Achilles Therapeutics
NASDAQ Capital Market
FAQ
What is the Aptorum share price?
As of Today at 18:18 UTC, shares in Aptorum are trading at $0.92. This share price information is delayed by 15 minutes.
How has the Aptorum share price performed this year?
Shares in Aptorum last closed at $0.92 and the price had moved by -88.61% over the past 365 days. In terms of relative price strength the Aptorum share price has underperformed the S&P500 Index by -89.48% over the past year.
What are the analyst and broker recommendations for Aptorum?
The overall consensus recommendation for Aptorum is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Aptorum dividend yield?
Aptorum does not currently pay a dividend.
Does Aptorum pay a dividend?
Aptorum does not currently pay a dividend.
When does Aptorum next pay dividends?
Aptorum does not currently pay a dividend.
How do I buy Aptorum shares?
To buy shares in Aptorum you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Aptorum?
As of the previous close price of $0.92, shares in Aptorum had a market capitalisation of $5.16m.
Where are Aptorum shares listed?
Here are the trading details for Aptorum:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: APM
What kind of share is Aptorum?
Based on an overall assessment of its quality, value and momentum Aptorum is currently classified as a Value Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Aptorum share price forecast for 2025?
The analyst consensus target price for shares in Aptorum is $80.00. That is 8595.65% above the last closing price of $0.92.
Analysts covering Aptorum currently have a consensus Earnings Per Share (EPS) forecast of -$0.70 for the next financial year.
Find out moreWhat is the trend in the Aptorum share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Aptorum. Over the past six months, its share price has underperformed the S&P500 Index by -57.32%.
As of the last closing price of $0.92, shares in Aptorum were trading -56.53% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Aptorum PE Ratio?
The Aptorum PE ratio based on its reported earnings over the past 12 months is 0.84. The shares last closed at $0.92.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Aptorum?
Aptorum's management team is headed by:
- Darren Lui - PRE
- Ian Huen - CEO
- Sabrina Khan - CFO
- Angel Ng - COO
- Clark Cheng - EDR
- Thomas Lee - OTH
- Douglas Arner - NID
- Charles Bathurst - NID
- Mirko Scherer - NID
- Justin Wu - NID